Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stronger therapy better for AML with normal genetics

30.11.2004


New research is helping select which therapies improve the chances of remission in the largest category of people affected by acute myeloid leukemia (AML) – those whose cancer cells have normal-looking chromosomes.



The findings suggest that people receiving more intense therapies are more likely to enter remission and to remain there longer than those receiving lower-dose therapies.

The study was published online Nov. 8 by the Journal of Clinical Oncology.


The Cancer and Leukemia Group B (CALGB) study was initiated by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James). It is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU cancer program.

Unexpectedly, the current study also found that patients who had an enlarged spleen at the time of their initial treatment were less likely to enter remission. AML patients are in remission when leukemic cells are not microscopically detectable among their bone-marrow cells.

“These preliminary findings raise the question of whether additional treatment directed specifically to the spleen might improve remission rates,” says first author Sherif S. Farag, assistant professor of internal medicine and a medical oncologist with the OSU CCC-James. “At this point, this is just a hypothesis that needs to be tested, but it may be that the spleen is a sanctuary site for leukemic cells and needs separate treatment.”

A diagnosis of AML routinely includes studying patients’ leukemic cells for chromosome damage, a process known as cytogenetic analysis. The information helps determine the best therapy and a patient’s chance of remission and cure. But 40 percent of AML patients have leukemic cells with normal-looking chromosomes. Without chromosomal abnormalities to guide treatment, several therapies are usually used.

“This study is important because it is the first large study to examine different types of therapy that is restricted to patients with normal chromosomes,” says Krzysztof Mrózek, an internationally recognized cytogeneticist, research scientist in internal medicine and one of the paper’s coauthors. “Yet, they make up the largest single group of people with AML.”

The multi-institutional study analyzed data from 490 patients treated for AML through five clinical trials conducted over nearly 20 years. Only adult patients under 60 years of age were included.

Overall, three quarters of the patients achieved complete remission. The average overall survival for the patients was 1.9 years, with 35 percent of patients still alive and disease-free after five years (these patients were considered cured).

The researchers first compared the outcomes of patients receiving one of two drug regimens given to bring the disease into remission. The study compared 350 patients receiving the drugs cytarabine plus daunorubicin to 140 patients receiving cytarabine plus increasing doses of both daunorubicin and etoposide. They found that both treatments induced remission about equally well. But to their surprise, they also found that patients with a normal spleen were four times more likely to enter remission than patients with an enlarged spleen, regardless of therapy. The researchers then looked at the second phase of treatment, known as intensification therapy, which is intended to keep patients in remission and to enhance the rate of cure.

The study compared four intensification therapies. Of these, the two more-intense therapies each produced longer remission periods and a better chance of cure than did the two less-intense therapies. That is, four cycles of high-dose cytarabine or one cycle of high-dose cytarabine and etoposide followed by stem-cell transplant were more effective than was one cycle of high-dose cytarabine alone. “There are many different approaches to post-remission therapy, and they include using fewer cycles of high-dose cytarabine or reducing the dose of the drug, but our study suggests these treatments are inferior,” Farag says.

At the same time, the study suggested that using very high doses of cytarabine may also be unnecessary. Using an intermediate dose seems equally effective but has fewer side effects, which can include toxicity to the kidneys and brain. “This has been suspected, but it hasn’t been carefully studied,” Farag says. “Again, we need a larger randomized study in the future to verify this, but our data show that we don’t need to push the dose to the maximum to have equal anti-leukemic effect.”

The study also suggested, however, that while two of the four therapies might produce longer remission periods—also known as periods of disease-free survival—no one treatment improved overall survival. The study followed patients for an average 7.4 years. “More research and some different strategies are still needed to give higher cure rates in these AML patients,” Farag says.

Statistician Amy S. Ruppert, research specialist with the OSU Comprehensive Cancer Center and CALGB, also contributed to this study.

Funding from the National Cancer Institute (NCI) supported this study. The CALGB is a multicenter NCI clinical trials group.

Darrell E. Ward | EurekAlert!
Further information:
http://www.osu.edu

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>